What Is Sermorelin?
GHRH Peptide Therapy · Last reviewed by the OPTML clinical team on April 29, 2026
Sermorelin acetate is a 29-amino-acid synthetic analog of growth-hormone-releasing hormone (GHRH). It binds the GHRH receptor on the anterior pituitary, stimulating endogenous growth hormone (GH) release in pulsatile, physiologic bursts. Unlike exogenous human growth hormone (HGH/somatropin), sermorelin preserves the pituitary feedback loop and does not produce supraphysiologic GH spikes. Originally FDA-approved in the 1990s as Geref for diagnostic use, it is now primarily prescribed by compounding pharmacies as a peptide therapy for adults with declining GH/IGF-1.
Indications and Common Uses
Sermorelin is used in adults with age-related decline in GH/IGF-1 (somatopause) where exogenous HGH is not indicated. Common goals:
- Improved sleep quality (deeper slow-wave sleep, where most natural GH is released).
- Recovery from training and physical stress.
- Body composition shifts (modest fat loss, lean mass support) over 3-6 months.
- Subjective energy and cognitive clarity.
- Skin and connective-tissue quality.
Mechanism
Sermorelin binds the GHRH receptor on somatotroph cells of the anterior pituitary, increasing intracellular cAMP and triggering GH release. Because the pituitary remains the regulator, GH release is pulsatile and subject to negative feedback from somatostatin and IGF-1, preserving the natural diurnal pattern. This is in contrast to:
- Exogenous HGH (somatropin): bypasses the pituitary; produces sustained, supraphysiologic GH levels.
Typical Dosing
| Parameter | Typical range |
|---|---|
| Dose | 200-500 mcg subcutaneous |
| Frequency | 5 nights/week, before bed (to align with natural GH pulse) |
| Cycle length | 3-6 months on, periodic breaks |
| Lab monitoring | IGF-1 baseline and at 8-12 weeks; aim for upper-quartile age-adjusted range |
Clinical Evidence
Sermorelin's strongest data is in pediatric GH deficiency, where it was used as both a diagnostic agent and treatment. In adults, controlled trials are limited but show:
- Increased GH pulse amplitude and modest increases in IGF-1 (Walker RF et al., 1994).
- Improvements in sleep architecture (slow-wave sleep) in older men (Vitiello MV et al., 2006).
- Modest improvements in body composition over 6 months in older adults with low IGF-1.
The evidence base for the consumer-facing peptide market is largely observational and clinic-derived. Sermorelin should be framed as a physiologic optimization tool, not a proven longevity intervention.
Side Effects and Risks
- Injection-site reactions (redness, swelling).
- Headache, flushing, nausea (typically transient).
- Vivid dreams (related to slow-wave sleep increase).
- Theoretical concerns about IGF-1 and cancer risk, patients with active malignancy should not use sermorelin or any GH-axis stimulator.
- Avoid in patients with active diabetic retinopathy or severe metabolic disease without specialty consultation.
Sermorelin vs. HGH
Exogenous HGH (somatropin) is FDA-approved for adult GH deficiency, AIDS wasting, short bowel syndrome, and pediatric indications. It is not legal to prescribe for "anti-aging" in the U.S. Sermorelin, by stimulating endogenous release, is a regulatory-distinct and physiologically gentler alternative, but its effect size is correspondingly smaller than exogenous HGH.
Considering sermorelin?
$189/mo · Compounded peptide · Physician-prescribed · IGF-1 monitoring included.
Start your consultation →References
- Walker RF, Yang SW, Bercu BB. Robust growth hormone (GH) secretion in aged female rats co-administered GH-releasing hexapeptide and growth hormone-releasing hormone. Life Sci. 1994;54(20):1553-1560.
- Vitiello MV, Moe KE, Merriam GR, et al. Growth hormone releasing hormone improves the cognition of healthy older adults. Neurobiol Aging. 2006;27(2):318-323.
- Veldhuis JD, Bowers CY. Integrating GHS into the GHRH/GH/IGF-I axis. Endocrine. 2010;38(1):1-16.
- Khorram O, Laughlin GA, Yen SS. Endocrine and metabolic effects of long-term administration of GHRH(1-29)-NH2 in age-advanced men and women. J Clin Endocrinol Metab. 1997;82(5):1472-1479.